A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis — PSO

Moderate-to-Severe Plaque Psoriasis Clinical Trial

Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Jaktinib in Patients With Moderate-to-Severe Plaque Psoriasis

Status Active, not recruiting

Clinical Trial Summary

This is study designed to investigate the efficacy and safety of Jaktinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety assessments.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Moderate-to-Severe Plaque Psoriasis
Psoriasis

Clinical Trial Details

NCT number	NCT04612699
Study type	Interventional
Source	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 11, 2021
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05787236` - A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting
Not yet recruiting	`NCT06258668` - Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Recruiting	`NCT06142357` - Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Recruiting	`NCT06182384` - A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices	Phase 1
Recruiting	`NCT03710681` - A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis	Phase 1
Not yet recruiting	`NCT04839016` - Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis	Phase 3